We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.75
Bid: 9.55
Ask: 10.00
Change: 0.00 (0.00%)
Spread: 0.45 (4.712%)
Open: 9.75
High: 0.00
Low: 0.00
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of share options and Directors' dealings

23 Nov 2016 16:21

RNS Number : 9836P
e-Therapeutics plc
23 November 2016
 

23 November 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Grant of share options and Directors' dealings

 

Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total of 10,310,000 ordinary shares of 0.1p each to certain executive directors and other employees (the "Optionholders"). The Optionholders are entitled to exercise their options in three tranches (as set out below) on or after the date specified below, if, at the time of exercise, the prevailing market price of the Company's ordinary shares is not less than the price set out below (the "Exercise Price"). Optionholders will be required to pay the Exercise Price to exercise their options.

Number of shares under option Exercise Price Exercise Date

3,436,666 16.76p 23 November 2018

3,436,667 20.95p 23 November 2018

3,436,667 25.14p 23 November 2019

Details of the individual options granted to executive directors are set out below:

Director Number of shares under option

Steve Medlicott 2,000,000

Sean Nicolson 750,000

The options referred to above are otherwise subject to the Rules of the Company's 2013 Performance Share Plan. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Steve Medlicott

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

 

 

 

 

Exercise price(s)

Volume(s)

 

£0.1676

666,666

 

 

£0.2095

666,667

 

 

£0.2514

666,667

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 2,000,000 options over ordinary shares

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

         

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Sean Nicolson

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

Exercise Price(s)

Volume(s)

 

£0.1676

250,000

 

 

£0.2095

250,000

 

 

£0.2514

250,000

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 750,000

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLRLTLVFIR
Date   Source Headline
20th Jun 20144:22 pmRNSHolding(s) in Company
20th Jun 20141:41 pmRNSHolding(s) in Company
18th Jun 20146:14 pmRNSAdditional Listing
30th May 20147:00 amRNSAnnual Financial Report and Notice of AGM
22nd May 20144:15 pmRNSIssue of Equity
12th May 20147:00 amRNSFull year results
8th May 20147:00 amBUSe-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial
2nd May 20144:46 pmRNSHolding(s) in Company
2nd May 20144:42 pmRNSHolding(s) in Company
2nd May 20144:29 pmRNSHolding(s) in Company
25th Apr 20147:00 amRNSNotice of Results
7th Apr 20141:07 pmRNSDirectorate Change
7th Apr 201411:46 amRNSDirectorate Change
31st Mar 20146:56 amBUSe-Therapeutics reports positive interim results from UK phase Ia trial of ETS2101 (dexanabinol) in a variety of solid tumours
26th Mar 20147:00 amBUSe-Therapeutics announces recruitment resumes into UK phase I ETS2101 cancer trial
10th Feb 20147:02 amBUSe-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers
24th Jan 20147:00 amBUSTemporary halt of recruitment into ETS2101 cancer trials because of drug supply issue - Patients already being treated will continue to be dosed
9th Jan 20142:34 pmRNSAdditional Listing
7th Jan 20147:00 amBUSStatement re e-Therapeutics provides update on ETS2101 phase I trial in brain cancer
31st Oct 20137:00 amBUSResearch Update
16th Oct 20137:00 amBUSHalf-yearly Report
30th Sep 20134:45 pmRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSNotice of Interim Results
6th Aug 201312:43 pmRNSAdditional Listing
1st Aug 20134:53 pmRNSDirector/PDMR Shareholding
30th Jul 20133:30 pmRNSDirector/PDMR Shareholding
25th Jul 201311:09 amRNSResult of AGM
24th Jul 201312:53 pmRNSDirector/PDMR Shareholding
3rd Jul 20134:41 pmRNSDirector/PDMR Shareholding
1st Jul 20139:00 amRNSNotice of AGM and Annual Report
21st Jun 20137:00 amRNSProactive Investors One2One Forum 26th Manchester
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
14th May 20137:00 amBUSPreliminary results for the year ended 31 January 2013
18th Apr 20137:00 amRNSNotice of Results
4th Apr 20135:18 pmRNSDirector/PDMR Shareholding
25th Mar 201310:44 amRNSHolding(s) in Company
18th Mar 20135:19 pmRNSIssue of Equity
13th Mar 20136:19 pmRNSHolding(s) in Company
6th Mar 201310:01 amRNSHolding(s) in Company
5th Mar 20135:44 pmRNSHolding(s) in Company
4th Mar 20133:31 pmRNSHolding(s) in Company
4th Mar 20133:23 pmRNSDirector/PDMR Shareholding
4th Mar 20132:56 pmRNSHolding(s) in Company
1st Mar 20137:00 amRNSCompletion of the Placings
28th Feb 201312:01 pmRNSCompletion of First Placing / Issue of Equity
27th Feb 201310:01 amRNSResult of General Meeting / Issue of Equity
22nd Feb 20132:51 pmRNSDirector/PDMR Shareholding
19th Feb 20139:45 amRNSDirector/PDMR Shareholding
15th Feb 20132:27 pmRNSDirector/PDMR Shareholding
14th Feb 20137:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.